Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Phase III KEYNOTE-394 trial of Keytruda meets primary endpoint in hepatocellular carcinoma – Merck Inc

Written by | 6 Oct 2021

Merck Inc announced that the Phase III KEYNOTE-394 trial investigating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in Asian patients with advanced hepatocellular carcinoma (HCC) previously treated with sorafenib met… read more.

Long-term data from PACIFIC phase III trial at ASCO showed 33% of NSCLC patients remained progression-free at five years – AstraZeneca

Written by | 9 Jun 2021

Updated results from the positive PACIFIC Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) demonstrated a sustained, clinically meaningful overall survival (OS) and progression-free survival (PFS) benefit at five… read more.

Phase III study of Covaxin reports efficacy of 80.6% in COVID-19 – Ocugen/Bharat Biotech

Written by | 8 Mar 2021

Ocugen announced that its co-development partner, Bharat Biotech, announced the results of the first interim analysis of its Phase III study of Covaxin, a whole virion inactivated COVID-19… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.